Abraxis buys Shimoda, subsidiary

Abraxis BioScience has completed acquisition of South Africa's Shimoda Biotech and its subsidiary, Platco Technologies. Abraxis bought the companies for $15 million up-front, plus potential additional payments upon the achievement of specified milestones. Shimoda is combining off-patent molecules with its drug delivery platform, in order to achieve faster onset and improved bioavailability characteristics of that platform. Platco Technologies focuses on the development of novel platinum-based anti-cancer drugs. Shimoda has one product on the market--Dyloject, an injectable painkiller for the treatment of post-surgical pain.

- here's the release

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.